Prof. Ron Levy's laboratory at Stanford developed a monoclonal antibody and hybridoma that targets CD37 (formerly known as MB-1). CD37 is expressed by mature human B cells in blood and tonsil, but not on T cells, thymocytes, granulocytes, or platelets.